Dharwad News Today

Vernal Keratoconjunctivitis Market, Share, Trends, Epidemiology Forecast Till 2030

 Breaking News
  • No posts were found

Vernal Keratoconjunctivitis Market, Share, Trends, Epidemiology Forecast Till 2030

July 01
04:30 2021
Vernal Keratoconjunctivitis Market, Share, Trends, Epidemiology Forecast Till 2030

DelveInsight Business Research LLP
DelveInsight’s “Vernal keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Vernal keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vernal Keratoconjunctivitis (VKC) is a bilateral, usually seasonally recurrent, allergic inflammation of the conjunctiva, characterized by limbal gelatinous hypertrophy and/or upper tarsal giant conjunctival papillae.

The Vernal keratoconjunctivitis market report provides current treatment practices, emerging drugs, Vernal keratoconjunctivitis market share of the individual therapies, current and forecasted Vernal keratoconjunctivitis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Vernal keratoconjunctivitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.


Vernal Keratoconjunctivitis Market Insight

The market size of Vernal Keratoconjunctivitis (VKC) in total markets in 2017 was USD 307.89 million

Vernal Keratoconjunctivitis Market Drivers

  • Rise in the Prevalence
  • Disease awareness and diagnosis
  • Research and development


Vernal Keratoconjunctivitis Market Barriers

  • Weak emerging drug pipeline
  • Diagnostic Barriers
  • Limited approved therapies


Vernal keratoconjunctivitis Market Outlook

Treatment of VKC requires multiple approaches that include conservative measures and pharmacologic treatment. Patients and parents should be made aware of the prolonged duration of disease, its chronic evolution, and possible complications. Treatment should be based on the duration and frequency of symptoms and the severity of corneal involvement.


Currently available topical drugs for allergic conjunctivitis belong to several pharmacologic classes, such as vasoconstrictorsantihistaminesmast cell stabilizers, ‘dual-acting’ agents (with antihistaminic and mast cell stabilizing properties), non-steroidal anti-inflammatory agentscorticosteroids, and immunosuppressive drugs.


Mast cell stabilizers are the first-line drugs for VKC. Several studies have demonstrated the efficacy of 2% and 4% sodium cromoglicate (DSCG, cromolyn), nedocromil sodium 2%, lodoxamide tromethamine 0.1%, and spaglumic acid 4%.


Ocular drugs with antihistaminic activity may offer therapeutic advantages to patients with allergic conjunctivitis, including VKC, by inhibiting proinflammatory cytokine secretion from conjunctival epithelial cells. The first-generation antihistamines pheniramine and antazoline have a long safety record. The newer antihistamines such as levocabastine hydrochloride 0.5% and emedastine difumarate 0.05% have a longer duration of action (4–6 h) and are better tolerated than their predecessors.


A meta-analysis of randomized clinical trials in VKC showed a large number of studies evaluated the efficacy of common anti-allergic eye drops (levocabastinelodoxamidemipragosideN-acetyl aspartyl glutamic acidnedocromil sodiumDCG). Among these, lodoxamide appeared to be the most effective.


Papilock mini and Verkazia both produced by Santen (Osaka, Japan) are specifically indicated for the treatment of VKC.

Generally, NSAIDs employed in ocular allergy treatment inhibit both cyclooxygenase (COX)-1 and COX-2 enzymes. Also, Ketorolacdiclofenac and pranoprofen may be valid alternatives to steroids, since they have a proven effect on itching, intercellular adhesion molecule-1 expression, and tear tryptase levels. Indomethacin 1%, ketorolac 0.5%, and diclofenac 0.1% have shown effectiveness in the treatment of VKC.


Aspirin 0.5–1 g/day has been shown as a steroid-sparing factor in the treatment of VKC; however, it should be used with caution because of the well-known possible side effects.


In severe cases, systemic treatment with T-lymphocyte signals transduction inhibitors such as Cyclosporine A or tacrolimus may ameliorate both the dermatologic and ocular manifestations in critical patients who are refractory to conventional treatment.

Omalizumab, an anti-IgE recombinant, humanized, non-anaphylactogenic antibody, directed against the receptor-binding domain of IgE, may be used in VKC patients with high levels of total serum IgE. Calcineurin inhibitors are off-label treatments in the European Union.


As discussed, the current treatment for VKC depends solely on the use of antihistamines, mast cell inhibitors, and several other classes. But till now the treatment is only supportive and is not that effective. But due to the advancement of technology and a better understanding of the disease, several companies are trying to modify the treatment of VKC.


Request for sample pages @ Vernal keratoconjunctivitis (VKC) Market Report 

Table of contents


1. Key Insights


2. Executive Summary of Vernal keratoconjunctivitis (VKC)


3. Vernal keratoconjunctivitis (VKC): Market Overview at a Glance


3.1. Total Market Share (%) Distribution of VKC in 2017


3.2. Total Market Share (%) Distribution of VKC in 2030


4. Disease Background and Overview: Vernal keratoconjunctivitis (VKC


5. Case Report


6. Epidemiology and Patient Population


7. United States Epidemiology


8. EU5 Epidemiology


8.1. Assumptions and Rationale


8.2. Germany Epidemiology


8.3. France Epidemiology


8.4. Italy Epidemiology


8.5. Spain Epidemiology


8.6. United Kingdom Epidemiology


9. Japan Epidemiology


10. MEA Region Epidemiology


10.1. Assumptions and Rationale


10.2.Saudi Arabia Epidemiology


10.3.Egypt Epidemiology


11. China Epidemiology


12. Russia Epidemiology


13. Current Treatment and Medical Practices


13.1. Treatment of VKC


13.2. Practical management of VKC


13.3. Treatment Guidelines


14. Unmet Needs


15. Marketed Drugs


15.1. Verkazia/Verkacia: Santen

15.2. Lodoxamide/Alomide: Novartis Pharmaceuticals/Alcon


15.3. Talymus/Tacrolimus: Senju Pharmaceutical


16. Emerging Drugs


16.1. Antolimab (AK002): Allakos


16.2. Bertilimumab/iCo-008: iCo Therapeutics


16.3. Nomacopan: Akari Therapeutics


17. Vernal Keratoconjunctivitis (VKC): 7MM Market Analysis


18. United States


19. EU-5 countries


19.1.Germany Market Size


19.2.France Market Size


19.3.Italy Market Size


19.4.Spain Market Size


19.5.United Kingdom Market Size


20. Japan


20.1. Japan Market Size


21. MEA countries Market Outlook


21.1.Saudi Arabia Market Size


21.2.Egypt Market Size


22. China: Market Outlook


22.1. China Market Size


23. Russia Market Outlook


23.1. Russia Market Size


24. Market Drivers


25. Market Barriers


26. Reimbursement and Market Access


27. SWOT Analysis


28. KOL Views


29. Appendix


30. DelveInsight Capabilities


31. Disclaimer


32. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/